Protara Therapeutics (TARA) Stock Forecast & Price Target

Compare

714 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TARA Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Protara

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TARA Stock 12 Month Forecast

Average Price Target

$22.00

▲(609.68% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Protara Therapeutics in the last 3 months. The average price target is $22.00 with a high forecast of $23.00 and a low forecast of $21.00. The average price target represents a 609.68% change from the last price of $3.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","24":"$24","6.75":"$6.75","12.5":"$12.5","18.25":"$18.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.75,12.5,18.25,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,4.593846153846154,6.127692307692308,7.661538461538461,9.195384615384615,10.72923076923077,12.263076923076923,13.796923076923077,15.330769230769231,16.864615384615384,18.39846153846154,19.932307692307692,21.466153846153844,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,4.516923076923077,5.973846153846154,7.430769230769231,8.887692307692308,10.344615384615386,11.801538461538462,13.258461538461539,14.715384615384616,16.172307692307694,17.62923076923077,19.086153846153845,20.54307692307692,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,4.44,5.82,7.200000000000001,8.58,9.96,11.340000000000002,12.72,14.100000000000001,15.480000000000002,16.86,18.240000000000002,19.62,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.14,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.93,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$23.00

Average Price Target$22.00

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Charles Zhu

LifeSci Capital

$22

Buy

609.68%

Upside

Reiterated

08/21/25

Protara Therapeutics' IV Choline Chloride: Promising Solution for Liver Dysfunction and Intestinal FailureWe recently interviewed three US-based KOLs with specialized training in, and experience prescribing, parenteral nutrion (PN) to 1) learn more about the state-of-the-art in PN care, 2) discuss unmet needs in the space (including around liver dysfuncon) 3) discuss clinical posioning and driv ers of adopon f or IV choline chloride, and 4) gauge reacons t o the THRIVE-3 trial design.

Soumit Roy

JonesTrading

$21

Buy

577.42%

Upside

Reiterated

08/15/25

Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (NASDAQ: TARA), Annexon Biosciences (NASDAQ: ANNX) and Agilent (NYSE: A)

Andres Y. Maldonado

H.C. Wainwright

$23

Buy

641.94%

Upside

Reiterated

08/11/25

Protara Therapeutics: Buy Rating Backed by Promising Clinical Advancements and Strategic Focus on Unmet Medical NeedsValuation and risks to reaching our price target. Our price target of $23 is based on an equally weighted composite of: (a) $19.32/share, as a 35x multiple of taxed and diluted $1.53 discounted back to and (b) an NPV of $26.0/share (discounted cash flow analysis using a 12.0% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Risks to achieving our price target include regulatory, commercial, clinical development, manufacturing, financial, liability and intellectual property risks. H.C. WAINWRIGHT & CO.

George Farmer

Scotiabank

$12

Buy

287.10%

Upside

Reiterated

05/09/25

Protara Therapeutics (TARA) Gets a Buy from Scotiabank

Li Watsek

Cantor Fitzgerald

―

Buy

―

Initiated

03/14/25

Protara Therapeutics initiated with an Overweight at Cantor FitzgeraldProtara Therapeutics initiated with an Overweight at Cantor Fitzgerald

Stacy Ku

TD Cowen

$30

Buy

867.74%

Upside

Reiterated

03/06/25

TD Cowen Keeps Their Buy Rating on Protara Therapeutics (TARA)

Leland Gershell

Oppenheimer

$25

Buy

706.45%

Upside

Reiterated

11/13/24

Oppenheimer Sticks to Their Buy Rating for Protara Therapeutics (TARA)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Charles Zhu

LifeSci Capital

$22

Buy

609.68%

Upside

Reiterated

08/21/25

Soumit Roy

JonesTrading

$21

Buy

577.42%

Upside

Reiterated

08/15/25

Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (NASDAQ: TARA), Annexon Biosciences (NASDAQ: ANNX) and Agilent (NYSE: A)

Andres Y. Maldonado

H.C. Wainwright

$23

Buy

641.94%

Upside

Reiterated

08/11/25

George Farmer

Scotiabank

$12

Buy

287.10%

Upside

Reiterated

05/09/25

Protara Therapeutics (TARA) Gets a Buy from Scotiabank

Li Watsek

Cantor Fitzgerald

―

Buy

―

Initiated

03/14/25

Protara Therapeutics initiated with an Overweight at Cantor FitzgeraldProtara Therapeutics initiated with an Overweight at Cantor Fitzgerald

Stacy Ku

TD Cowen

$30

Buy

867.74%

Upside

Reiterated

03/06/25

TD Cowen Keeps Their Buy Rating on Protara Therapeutics (TARA)

Leland Gershell

Oppenheimer

$25

Buy

706.45%

Upside

Reiterated

11/13/24

Oppenheimer Sticks to Their Buy Rating for Protara Therapeutics (TARA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protara Therapeutics

1 Month

xxx

Success Rate

5/14 ratings generated profit

Average Return

+2.88%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 35.71% of your transactions generating a profit, with an average return of +2.88% per trade.

3 Months

xxx

Success Rate

6/14 ratings generated profit

Average Return

+30.00%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +30.00% per trade.

1 Year

Stacy KuTD Cowen

Success Rate

3/5 ratings generated profit

Average Return

+1.96%

reiterated a buy rating 6 months ago

Copying Stacy Ku's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +1.96% per trade.

2 Years

xxx

Success Rate

7/14 ratings generated profit

Average Return

+7.51%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +7.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TARA Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TARA has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TARA average Analyst price target in the past 3 months is 22.00.

Each month's total comprises the sum of three months' worth of ratings.

TARA Financial Forecast

TARA Earnings Forecast

Next quarter’s earnings estimate for TARA is -$0.38 with a range of -$0.41 to -$0.36. The previous quarter’s EPS was -$0.35. TARA beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.06% of the time in the same period. In the last calendar year TARA has Outperformed its overall industry.

No data currently available

TARA Sales Forecast

Next quarter’s sales forecast for TARA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TARA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.23% of the time in the same period. In the last calendar year TARA has Preformed in-line its overall industry.

TARA Stock Forecast FAQ

What is TARA’s average 12-month price target, according to analysts?

Based on analyst ratings, Protara Therapeutics’s 12-month average price target is 22.00.

What is TARA’s upside potential, based on the analysts’ average price target?

Protara Therapeutics has 609.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TARA a Buy, Sell or Hold?

Protara Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Protara Therapeutics’s price target?

The average price target for Protara Therapeutics is 22.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $23.00 ,the lowest forecast is $21.00. The average price target represents 609.68% Increase from the current price of $3.1.

What do analysts say about Protara Therapeutics?

Protara Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of TARA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Protara Therapeutics (TARA) Stock Forecast & Price Target

TARA Analyst Ratings

TARA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Protara Therapeutics

TARA Analyst Recommendation Trends

TARA Financial Forecast

TARA Earnings Forecast

TARA Sales Forecast

TARA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts